GT Biopharma (GTBP) Set to Announce Earnings on Friday

GT Biopharma (NASDAQ:GTBP) will likely be posting its Q3 2026 results before the market opens on Friday, November 13th. Analysts expect GT Biopharma to announce earnings of ($2.50) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

GT Biopharma (NASDAQ:GTBP) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04).

GT Biopharma Stock Performance

NASDAQ:GTBP opened at $3.95 on Thursday. GT Biopharma has a fifty-two week low of $3.86 and a fifty-two week high of $28.75. The firm has a 50-day simple moving average of $6.31 and a two-hundred day simple moving average of $9.29.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of GT Biopharma to a “strong sell” rating in a research note on Saturday, September 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research centers on natural killer (NK) cells, a component of the immune system that can recognize and destroy abnormal cells. GT Biopharma’s principal technology is its TriKE (trispecific killer engager) platform. These engineered molecules are designed to bind a cancer-associated target, activate NK cells through the CD16 receptor, and enhance NK-cell activity through an interleukin-15 component.